Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIXT Lixte Biotechnology Holdings Inc.

Closed 04-28 16:00:00 EDT

3.60

-0.20

-5.26%

盘后3.60

+0.000.00%

18:38 EDT

High3.69	Low3.41	Vol23.13K
Open3.69	D1 Closing3.80	Amplitude7.24%
Mkt Cap41.82M	Tradable Cap41.78M	Total Shares11.62M
T/O82.95K	T/O Rate0.20%	Tradable Shares11.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LIXT","market":"US","secType":"STK","nameCN":"Lixte Biotechnology Holdings Inc.","latestPrice":3.6,"timestamp":1777406400000,"preClose":3.8,"halted":0,"volume":23126,"hourTrading":{"tag":"盘后","latestPrice":3.6,"preClose":3.6,"latestTime":"18:38 EDT","volume":7,"amount":25.2,"timestamp":1777415925011,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.052631578947368356,"floatShares":11606900,"shares":11617944,"eps":-1.259999,"marketStatus":"Closed","change":-0.2,"latestTime":"04-28 16:00:00 EDT","open":3.685,"high":3.685,"low":3.41,"amount":82949.835916,"amplitude":0.072368,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.259999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777449600000},"marketStatusCode":5,"adr":0,"listingDate":1606280400000,"exchange":"NASDAQ","adjPreClose":3.8,"postHourTrading":{"tag":"盘后","latestPrice":3.6,"preClose":3.6,"latestTime":"18:38 EDT","volume":7,"amount":25.2,"timestamp":1777415925011,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.480674},"requestUrl":"/m/hq/s/LIXT","defaultTab":"news","newsList":[{"id":"2630299319","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2630299319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630299319?lang=en_us&edition=fundamental","pubTime":"2026-04-28 01:30","pubTimestamp":1777311034,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 27th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ:LIXT) is advancing the precision oncology lan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-unlocking-new-potential-in-precision-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-unlocking-new-potential-in-precision-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQY","PSQ","NVIW.SI","QYLG","QID","QQQJ","LIXT","QDTE","BK4139","QQQ","QQQM","QQQE","SQQQ",".IXIC","NDX","QLD","FTEC","QQQY","JEPQ","ONEQ","GPIQ","MNQmain","IYW","NQmain","QQQA","TQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629029614","title":"Greenland Mines appoints Jason D. Sawyer to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2629029614","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629029614?lang=en_us&edition=fundamental","pubTime":"2026-04-23 01:14","pubTimestamp":1776878060,"startTime":"0","endTime":"0","summary":"Greenland Mines appointed Jason D. Sawyer to board of directors effective April 17, 2026.Sawyer is general manager of Access Alternative Group, a Nassau-based venture investment and advisory firm.He currently serves as CEO and a director of GridAI Technologies.Sawyer also holds board roles at The FUTR Corp., Lixte Biotechnology Holdings, Perpetuals.com.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenland Mines Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL8DG90t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRML","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629778555","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2629778555","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629778555?lang=en_us&edition=fundamental","pubTime":"2026-04-21 02:00","pubTimestamp":1776708025,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 20th, 2026, FinanceWire Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ:LIXT) spent 20...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-positions-lb-100-as-novel-approach-in-cancer-treatment-landscape?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-positions-lb-100-as-novel-approach-in-cancer-treatment-landscape?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","MNQmain","QID",".IXIC","LB","TQQQ","SQQQ","PSQ","NVIW.SI","LIXT","NQmain","NDX","QQQA","TQQY","QQQ","JEPQ","QDTE","FTEC","QQQE","QQQM","QLD","GPIQ","BK4139","IYW","BK4233","QYLG","ONEQ","QQQJ","QQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628400781","title":"Lixte Biotechnology replaces stock options with RSUs for executives, directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2628400781","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628400781?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:06","pubTimestamp":1776456402,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings swapped previously granted stock options for fully vested restricted share units on April 15, 2026.Chief Executive Officer Geordan Pursglove had 350,000 options cancelled, replaced with 350,000 RSUs.Chief Financial Officer Peter Stazzone had 50,000 options cancelled, replaced with 50,000 RSUs.Directors received replacement awards totaling 100,000 RSUs, matching 100,000 options cancelled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL3CCjvf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627527124","title":"LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627527124","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627527124?lang=en_us&edition=fundamental","pubTime":"2026-04-14 00:30","pubTimestamp":1776097818,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 13th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ:LIXT), a clinical-stage pharmaceutical compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-reports-interim-ovarian-cancer-trial-results-at-sgo-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-reports-interim-ovarian-cancer-trial-results-at-sgo-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONEQ",".IXIC","QID","QQQA","QDTE","MNQmain","NQmain","FTEC","QLD","NVIW.SI","BK4139","QQQY","QQQM","JEPQ","LIXT","GPIQ","QQQE","QQQ","QQQJ","IYW","SQQQ","NDX","PSQ","TQQQ","TQQY","QYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045886","title":"Lixte reports favorable interim results for LB-100 plus dostarlimab ovarian cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045886","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627045886?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:06","pubTimestamp":1776081983,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology reported preliminary results already presented at Society of Gynecological Cancer conference held April 10-13, 2026 in San Juan for a trial combining LB-100 with GSK’s PD-1 drug Dostarlimab in ovarian clear cell carcinoma.Interim readout showed an acceptable safety profile and signs of disease control, supporting continued development of combination regimen.Enrollment reached 21 planned participants, with 20 included in interim efficacy analysis.Program is expanding with an additional 21-patient cohort now enrolling at higher LB-100 exposure to further test activity in patients lacking genetic reduction in PP2A.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLSD8Ml:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BGHQF748.EUR","BK4112","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","LIXT","BK4585","LU2210150020.SGD","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","SG9999014021.USD","SG9999014005.SGD","BK4139","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627430432","title":"Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627430432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627430432?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:00","pubTimestamp":1776081604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUA8SS1VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626411111","title":"Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2626411111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626411111?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:00","pubTimestamp":1775836809,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 10th, 2026, FinanceWire LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotech-holdings-nasdaq-lixt-advances-precision-oncology-strategy-with-lb-100-expands-clinical-and-strategic-partnerships?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotech-holdings-nasdaq-lixt-advances-precision-oncology-strategy-with-lb-100-expands-clinical-and-strategic-partnerships?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","QQQA","FTEC","LIXT","QQQJ","QDTE","IYW","BK4588","GPIQ","NDX","QID","XBI","BK4139","LB","BK4233","JEPQ","NVIW.SI","TQQQ","QLD","QQQE","SQQQ","QQQM","QQQ","BK4581","QYLG","QQQY","BK4213","TQQY",".IXIC","MNQmain","PSQ","BK4585","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624001115","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2624001115","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624001115?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:00","pubTimestamp":1775142017,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 2nd, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-files-2025-form-10-k-highlights-transformational-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-files-2025-form-10-k-highlights-transformational-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QYLG","QID","QQQJ","NDX","NQmain","QQQE","SQQQ","TQQQ","BK4139","QQQ","QDTE","MNQmain",".IXIC","QQQM","LIXT","JEPQ","PSQ","FTEC","QLD","IYW","QQQY","NVIW.SI","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624167590","title":"LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2624167590","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624167590?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:19","pubTimestamp":1775042368,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 31st, 2026, FinanceWire Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challeng...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-strengthens-oncology-pipeline-through-expanded-lb-100-clinical-trials-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-strengthens-oncology-pipeline-through-expanded-lb-100-clinical-trials-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain",".IXIC","IYW","BK4233","LB","SQQQ","BK4139","NVIW.SI","JEPQ","FTEC","QLD","MNQmain","LIXT","QDTE","QQQM","QQQE","QID","PSQ","QQQ","QQQJ","NDX","BK4213","QYLG","TQQQ","QQQY","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624559781","title":"Lixte FY25 net loss widens to $6M; operating loss climbs to $5.1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2624559781","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624559781?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:49","pubTimestamp":1774997347,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology posted net loss of $6M for fiscal 2025, widening 67.6%.Revenue was unchanged at no revenue, while operating loss deepened to $5.1M.General and administrative expense climbed to $4.9M, while research and development expense fell to less than $1M.Cash totaled $5.1M at year-end, following $10.3M of financing inflows during 2025.Business updates included adding Northwestern’s Lurie Cancer Center as a second site in LB-100 ovarian clear cell cancer trial, while expecting about $2M over 24 months to recommission Liora’s LiGHT proton therapy prototype.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL7Fd3Tm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622104876","title":"Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2622104876","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622104876?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:00","pubTimestamp":1774627211,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 27th, 2026, FinanceWire LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectivene...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotech-nasdaq-lixt-advances-precision-oncology-with-lb-100-strengthens-position-through-liora-technologies-partnership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotech-nasdaq-lixt-advances-precision-oncology-with-lb-100-strengthens-position-through-liora-technologies-partnership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SQQQ","XBI","BK4585","GPIQ","PSQ","QYLG","QID","QDTE","QLD","BK4588","QQQE","MNQmain",".IXIC","BK4213","LIXT","BK4581","BK4139","QQQJ","NVIW.SI","LB","BK4233","FTEC","JEPQ","NQmain","QQQY","IYW","TQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621148700","title":"LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2621148700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621148700?lang=en_us&edition=fundamental","pubTime":"2026-03-24 00:00","pubTimestamp":1774281610,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 23rd, 2026, FinanceWire Recent research shows how chemotherapy and immunotherapy can complement each other when...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-advances-pp2a-inhibition-strategy-in-evolving-oncology-landscape?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-advances-pp2a-inhibition-strategy-in-evolving-oncology-landscape?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSYW.SI","BK4139","GPIQ","PSQ","QQQY","SQQQ","QQQE","USAW.SI","MNQmain","JEPQ","QYLG","TQQQ","QQQJ",".IXIC","NQmain","LIXT","QLD","USJW.SI","QID","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621548097","title":"Lixte Biotechnology Raises CEO Compensation Amid Leadership Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2621548097","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621548097?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:33","pubTimestamp":1774038835,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings ( ($LIXT) ) has shared an announcement. On March 18, 2026, Lixte Biotechnology Holdings, Inc. amended the employment a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-raises-ceo-compensation-amid-leadership-support?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-biotechnology-raises-ceo-compensation-amid-leadership-support?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618130848","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130848","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130848?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:42","pubTimestamp":1773322938,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nAQN2LPUEK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618296117","title":"Lixte Amends Share Exchange, Clarifies Liora Ownership Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2618296117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618296117?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:43","pubTimestamp":1773175399,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings ( ($LIXT) ) just unveiled an update. On March 6, 2026, Lixte Biotechnology Holdings, Liora Technologies Europe and Orb...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-amends-share-exchange-clarifies-liora-ownership-structure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-amends-share-exchange-clarifies-liora-ownership-structure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618646952","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618646952?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:00","pubTimestamp":1773158410,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 10th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ:LIXT), a clinical-stage pharmaceutical company, re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-adds-innovative-light-therapy-to-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-adds-innovative-light-therapy-to-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JEPQ","TSYW.SI","BK4139",".IXIC","QLD","QQQE","NQmain","TQQQ","USAW.SI","USJW.SI","GPIQ","PSQ","SQQQ","QYLG","QID","QQQY","NVIW.SI","LIXT","QQQJ","MNQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618317678","title":"LIXTE Biotechnology (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2618317678","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618317678?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:00","pubTimestamp":1773072015,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 9th, 2026, FinanceWire The promise of immunotherapy lies in its ability to harness the body’s own immune ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-advances-lead-compound-in-tumor-immunogenicity-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-advances-lead-compound-in-tumor-immunogenicity-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QYLG","USJW.SI","QLD","USAW.SI","QID","QQQJ","QQQE","SQQQ",".IXIC","QQQY","PSQ","GPIQ","TQQQ","BK4139","NQmain","TSYW.SI","MNQmain","JEPQ","QYLD","LIXT","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618626333","title":"Powell Max names Geordan Pursglove chairman and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2618626333","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618626333?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059456,"startTime":"0","endTime":"0","summary":"Powell Max appointed Geordan Pursglove as chairman and CEO. Pursglove is chairman and CEO of Lixte Biotechnology and managing director of 2GP Group. The company also added Andrew Hancox, Phillip Balatsos, Caroline Castleforte, and Lourdes Felix to its board. Hancox is founder and managing member of Block 8 Ventures, while Felix is CEO and CFO of BioCorRx.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLbpJfm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","LIXT","BICX","IE00B64PRP62.GBP","PMAX","SG9999014039.USD","BK4185","LU2095319765.USD","BK4588","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618362660","title":"Powell Max Limited Successfully Repositions for Its Next Phase of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2618362660","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618362660?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059400,"startTime":"0","endTime":"0","summary":"Hong Kong, TX, March  09, 2026  (GLOBE NEWSWIRE) --  Powell Max Limited (Nasdaq: PMAX)(“Powell Max” or the “Company”), a financial communications services provider, is pleased to provide the following","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251816/0/en/Powell-Max-Limited-Successfully-Repositions-for-Its-Next-Phase-of-Growth.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["A","BK4134","ALBT","IE00BN0W2V16.EUR","LU2089279066.USD","BK4079","BK4139","LU2041044095.USD","GRDX","IE00BN0W2W23.USD","BK4233","LU2092937221.SGD","LU2413666426.HKD","BK4567","LIXT","BK4588","LRHC","LU0347712357.USD","BK4112","LU2229751404.USD","LU1165135440.EUR","LU1543694498.USD","BK4585","PMAX","BK4096","LU2413666699.HKD","CISO","IE00BN0W2T93.GBP","BK4205","LU1721428933.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lixte.com","stockEarnings":[{"period":"1week","weight":0.1063},{"period":"1month","weight":0.2298},{"period":"3month","weight":0.1111},{"period":"6month","weight":-0.1264},{"period":"1year","weight":1.9687},{"period":"ytd","weight":-0.0331}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.153774},{"month":2,"riseRate":0.625,"avgChangeRate":0.06495},{"month":3,"riseRate":0.5,"avgChangeRate":-0.03366},{"month":4,"riseRate":0.375,"avgChangeRate":-0.062197},{"month":5,"riseRate":0.375,"avgChangeRate":-0.005082},{"month":6,"riseRate":0.5,"avgChangeRate":0.031165},{"month":7,"riseRate":0.625,"avgChangeRate":0.400968},{"month":8,"riseRate":0.5,"avgChangeRate":0.097631},{"month":9,"riseRate":0.375,"avgChangeRate":0.00973},{"month":10,"riseRate":0.375,"avgChangeRate":-0.019298},{"month":11,"riseRate":0.375,"avgChangeRate":-0.035386},{"month":12,"riseRate":0.25,"avgChangeRate":-0.145393}],"exchange":"NASDAQ","name":"Lixte Biotechnology Holdings Inc.","nameEN":"Lixte Biotechnology Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lixte Biotechnology Holdings Inc.,LIXT,Lixte Biotechnology Holdings Inc.股票,Lixte Biotechnology Holdings Inc.股票老虎,Lixte Biotechnology Holdings Inc.股票老虎国际,Lixte Biotechnology Holdings Inc.行情,Lixte Biotechnology Holdings Inc.股票行情,Lixte Biotechnology Holdings Inc.股价,Lixte Biotechnology Holdings Inc.股市,Lixte Biotechnology Holdings Inc.股票价格,Lixte Biotechnology Holdings Inc.股票交易,Lixte Biotechnology Holdings Inc.股票购买,Lixte Biotechnology Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}